N
0R6Y
vs
O
Oslo OBX
Over the past 12 months, 0R6Y has significantly outperformed Oslo OBX, delivering a return of +100% compared to the Oslo OBX's +19% growth.
Stocks Performance
0R6Y vs Oslo OBX
Performance Gap
0R6Y vs Oslo OBX
Performance By Year
0R6Y vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Nordic Nanovector ASA
Glance View
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 40 full-time employees. The company went IPO on 2014-07-07. The company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). The company is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. The company has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.
